| First Author | Gritsman K | Year | 2014 |
| Journal | J Clin Invest | Volume | 124 |
| Issue | 4 | Pages | 1794-809 |
| PubMed ID | 24569456 | Mgi Jnum | J:209632 |
| Mgi Id | MGI:5568201 | Doi | 10.1172/JCI69927 |
| Citation | Gritsman K, et al. (2014) Hematopoiesis and RAS-driven myeloid leukemia differentially require PI3K isoform p110alpha. J Clin Invest 124(4):1794-809 |
| abstractText | The genes encoding RAS family members are frequently mutated in juvenile myelomonocytic leukemia (JMML) and acute myeloid leukemia (AML). RAS proteins are difficult to target pharmacologically; therefore, targeting the downstream PI3K and RAF/MEK/ERK pathways represents a promising approach to treat RAS-addicted tumors. The p110alpha isoform of PI3K (encoded by Pik3ca) is an essential effector of oncogenic KRAS in murine lung tumors, but it is unknown whether p110alpha contributes to leukemia. To specifically examine the role of p110alpha in murine hematopoiesis and in leukemia, we conditionally deleted p110alpha in HSCs using the Cre-loxP system. Postnatal deletion of p110alpha resulted in mild anemia without affecting HSC self-renewal; however, deletion of p110alpha in mice with KRASG12D-associated JMML markedly delayed their death. Furthermore, the p110alpha-selective inhibitor BYL719 inhibited growth factor-independent KRASG12D BM colony formation and sensitized cells to a low dose of the MEK inhibitor MEK162. Furthermore, combined inhibition of p110alpha and MEK effectively reduced proliferation of RAS-mutated AML cell lines and disease in an AML murine xenograft model. Together, our data indicate that RAS-mutated myeloid leukemias are dependent on the PI3K isoform p110alpha, and combined pharmacologic inhibition of p110alpha and MEK could be an effective therapeutic strategy for JMML and AML. |
